Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
Journal: Nature medicine
Published: June 02, 2021
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia.
Journal: JCO oncology practice
Published: October 30, 2020
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 27, 2020
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.
Journal: Journal of clinical medicine
Published: March 19, 2020
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
Journal: Leukemia
Published: February 13, 2019
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 21, 2017
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Journal: The Lancet. Haematology
Published: September 12, 2017
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.
Journal: Clinical lymphoma, myeloma & leukemia
Published: June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Journal: The Lancet. Haematology
Published: March 22, 2017
Last Updated: 09/26/2026